Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Phase 2 Not yet recruiting

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

126 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07402070 2026-02-11

IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

10 enrolled

Thoracic

Resectable Stage II-III Non-small Cell Lung Cancer

NCT07360743 2026-02-10

META-1

Phase 2 Not yet recruiting

275 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07398560 2026-02-10

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

Phase 2 Not yet recruiting

47 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07393555 2026-02-06

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2 Not yet recruiting

117 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07388875 2026-02-05

SKB264-ANLO

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07381543 2026-02-04

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone

Phase 2 Not yet recruiting

76 enrolled

Thoracic

Localized Small Cell Lung Cancer

NCT07379398 2026-01-30

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

28 enrolled

Thoracic

NSCLC

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Phase 2 Not yet recruiting

31 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

60 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07357532 2026-01-22

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Phase 2 Not yet recruiting

44 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Phase 2 Not yet recruiting

25 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

120 enrolled

Thoracic

NSCLC

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2 Not yet recruiting

156 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07298148 2026-01-21

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

Phase 2 Not yet recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07354919 2026-01-21

AxeCan

Phase 2 Not yet recruiting

34 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07355205 2026-01-21

FLINN

Phase 2 Not yet recruiting

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07353476 2026-01-20

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

Phase 2 Not yet recruiting

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07349225 2026-01-16

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Not yet recruiting

46 enrolled

Thoracic

ES-SCLC

NCT07343479 2026-01-15

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Phase 2 Not yet recruiting

45 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07336732 2026-01-14

KANNON-5

Phase 2 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07333651 2026-01-12

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

Phase 2 Not yet recruiting

90 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07324629 2026-01-09

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Thymoma

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

GIVEN

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

ALISCA-Lung2

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

P4-PACIFIC

CURB-TKI

T-BRAIN

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

FMT-LUNG

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

CECYDE

A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

LAG-MAPS

IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer

META-1

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

SKB264-ANLO

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

AxeCan

FLINN

Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

KANNON-5

125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer